Postprandial hyperglycemia and glycemic variability: Should we care?

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Standl, Eberhard ^a   Schnell, Oliver ^a   Ceriello, Antonio ^b  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; ROSIGLITAZONE; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOOD CLOTTING; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF MONITORING; TREATMENT OUTCOME; BLOOD; METABOLISM; PHYSIOLOGY;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA;

EID: 79959774659     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s206     Document Type: Article

References (60)

1. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000;43:1455-1469 (Pubitemid 32734852)
2. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials. Lancet 2009;373:1765-1772
3. Control Group; Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298
4. Weber Ch, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009;11: 623-633
5. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
6. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181 (Pubitemid 40615551)
7. Wójcicki JM. "J"-index: a new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995;27:41-42
8. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 1970;19:644-655
9. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253-263 (Pubitemid 40586369)
10. Kovatchev BP, Otto E, Cox D, Gonder- Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438 (Pubitemid 44912248)
11. Coutinho M, Gerstein HC,Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22: 233-240 (Pubitemid 29056916)
12. The DECODE study group; European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-621
13. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999;22:920-924 (Pubitemid 29241045)
14. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151-157 (Pubitemid 47057520)
15. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009;52:415-424
16. Smith NL, Barzilay JI, Shaffer D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 2002;162:209-216 (Pubitemid 34098191)
17. Vaccaro O, Ruth KJ, Stamler J. Relationship of postload plasma glucose to mortality with 19-yr follow-up: comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. Diabetes Care 1992;15: 1328-1334
18. Lowe LP, Liu K, Greenland P,Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-169 (Pubitemid 27051554)
19. Orencia AJ,DaviglusML, Dyer AR,Walsh M, Greenland P, Stamler J. One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study. J Clin Epidemiol 1997;50:1369-1376 (Pubitemid 28034990)
20. Nakagami T; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-394
21. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25: 1845-1850 (Pubitemid 41071098)
22. Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and totalmortality: the Honolulu Heart Program. Diabetes Care 1999;22:1262-1265 (Pubitemid 29350234)
23. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with allcause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931 (Pubitemid 29369599)
24. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated postchallenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42:1050-1054 (Pubitemid 29408800)
25. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-367 (Pubitemid 28101069)
26. Qiao Q, Pyörälä K, Pyörälä M, et al. Twohour glucose is a better risk predictor for incident coronary heart disease and cardiovascularmortality than fasting glucose. Eur Heart J 2002;23:1267-1275 (Pubitemid 35238508)
27. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care 1998;21:1236-1239 (Pubitemid 28365676)
28. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91: 813-819 (Pubitemid 43357744)
29. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001; 24:1397-1402 (Pubitemid 33716427)
30. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006;29:26-31 (Pubitemid 44033426)
31. HåheimLL,Holme I,Hjermann I, Leren P. Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke 1995;26:774-777
32. HanefeldM, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year followup. Diabetologia 1996;39:1577-1583 (Pubitemid 26397370)
33. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36: 3008-3013
34. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-252 (Pubitemid 44148168)
35. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-913 (Pubitemid 33636068)
36. Kilpatrick ES, Rigby AS,Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486-1490 (Pubitemid 44127568)
37. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001;44:1215-1220 (Pubitemid 33010497)
38. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 1995;268:E1167-E1173
39. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-154
40. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171-175 (Pubitemid 38221817)
41. Wascher TC, Schmoelzer I, Wiegratz A, et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005;35:551-557 (Pubitemid 41243298)
42. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005;112:179-184 (Pubitemid 40982299)
43. Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 2006;29: 95-100 (Pubitemid 44033438)
44. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-2804 (Pubitemid 37339710)
45. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005;183:259-267 (Pubitemid 41579276)
46. Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 2006;22:198-203 (Pubitemid 43805400)
47. Azuma K, Watada H, Niihashi M, et al. A new En face method is useful to quantitate endothelial damage in vivo. Biochem Biophys Res Commun 2003;309:384-390 (Pubitemid 37028319)
48. Azuma K, Kawamori R, Toyofuku Y, et al. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol 2006;26:2275-2280 (Pubitemid 44465722)
49. Mita T, Otsuka A, Azuma K, et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2007;358:679-685 (Pubitemid 46802446)
50. Azuma K, Toyofuku Y, Iesaki T, et al. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto- Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 2006;345:688-693 (Pubitemid 43776986)
51. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072 (Pubitemid 35192812)
52. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patientswith type 1 diabetes. Diabetologia 2008;51:183-190 (Pubitemid 50002199)
53. Ihnat MA, Kaltreider RC, Thorpe JE, et al. Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose. Amer J Biochem Biotech 2007; 3:16-23 (Pubitemid 46515632)
54. Ceriello A, Morocutti A, Mercuri F, et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000; 49:2170-2177
55. Meugnier E, Faraj M, Rome S, et al. Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007;56:992-999 (Pubitemid 46525077)
56. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDMtrial. JAMA 2003;290:486-494 (Pubitemid 37430502)
57. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386
58. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476
59. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298: 1189-1195 (Pubitemid 47403105)
60. Home PD, Pocock SJ, Beck-Nielsen H, et al.; for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135